Human immunodeficiency virus and renal transplantation

Kidney International

Volumn 76, Issue 8, 2009, Pages 907-910

  Dinavahi, Rajani V ^a,b   Mehrotra, Anita ^a   Murphy, Barbara T ^a   Huprikar, Shirish ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Box 1243   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATOVAQUONE; AZITHROMYCIN; CALCINEURIN INHIBITOR; CLARITHROMYCIN; COTRIMOXAZOLE; CYCLOSPORIN; DAPSONE; EFAVIRENZ; FOLINIC ACID; HIGH DENSITY LIPOPROTEIN; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PYRIMETHAMINE; RAPAMYCIN; STEROID; TENOFOVIR;

ARTICLE; ATYPICAL MYCOBACTERIOSIS; DISEASE ASSOCIATION; HEMODIALYSIS; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY TRANSPLANTATION; MALIGNANT NEOPLASTIC DISEASE; OPPORTUNISTIC INFECTION; PNEUMOCYSTOSIS; PRIORITY JOURNAL; TOXOPLASMOSIS;

AIDS-ASSOCIATED NEPHROPATHY; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHOLESTEROL; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; GRAFT SURVIVAL; HIV INFECTIONS; HUMANS; HYPOLIPIDEMIC AGENTS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; RENAL DIALYSIS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 70349706084     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.184     Document Type: Article

References (20)

1. Ortiz C, Meneses R, Jaffe D et al. Outcome of patients with human immunodeficiency virus on maintenance hemodialysis. Kidney Int 1988; 34: 248-253.
2. USRDS Annual Data Reports 1985-2000. http://www.usrds.org/adr.htm.
3. Ahuja TS, Grady J, Khan S. Changing trends in the survival of dialysis patients with human immunodeficiency virus in the United States. J Am Soc Nephrol 2002; 13: 1889-1893.
4. Abbott KC, Swanson SJ, Agodoa LY et al. Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. J Am Soc Nephrol 2004; 15: 1633-1639.
5. Spital A. Should all human immunodeficiency virus-infected patients with end-stage renal disease be excluded from transplantation?The views of U.S. transplant centers. Transplantation 1998; 65: 1187-1191.
6. Roland MC, Ragni L, Rohal M et al. Solid organ transplantation in HIV infected recipients: forty-seven cases in the HAART Era. Presented at the XIV International AIDS Conference, Barcelona, Spain, July 7-12 2002.
7. Stock PG, Roland ME, Carlson L et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation 2003; 76: 370-375.
8. Qiu J, Terasaki PI, Waki K et al. HIV-positive renal recipients can achieve survival rates similar to those of HIV-negative patients. Transplantation 2006; 81: 1658-1661.
9. Kumar MS, Sierka DR, Damask AM et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int 2005; 67: 1622-1629.
10. Roland ME, Barin B, Carlson L et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplantation 2008; 8: 355-365.
11. Locke JE, Montgomery RA, Warren DS et al. Renal transplant in HIVpositive patients: long-term outcomes and risk factors for graft loss. Arch Surg 2009; 144: 83-86.
12. Swanson SJ, Kirk AD, Ko CW et al. Impact of HIV seropositivity on graft and patient survival after cadaveric renal transplantation in the United States in the pre highly active antiretroviral therapy (HAART) era: an historical cohort analysis of the United States Renal Data System. Transpl Infect Dis 2002; 4: 144-147.
13. Erice A, Rhame FS, Heussner RC et al. Human immunodeficiency virus infection in patients with solid-organ transplants: report of five cases and review. Rev Infect Dis 1991; 13: 537-547.
14. Tzakis AG, Cooper MH, Dummer JS et al. Transplantation in HIV+ Patients. Transplantation 1990; 49: 354-358.
15. Solid organ transplantation in the HIV-infected patient. Am J Transplantation 2004; 4(Suppl 10): 83-88.
16. Carter JT, Melcher ML, Carlson LL et al. Thymoglobulin-associated Cd4+ Tcell depletion and infection risk in HIV-infected renal transplant recipients. Am J Transplantation 2006; 6: 753-760.
17. Groux H, Torpier G, Monte D et al. Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med 1992; 175: 331-340.
18. Izzedine H, Launay-Vacher V, Baumelou A et al. Antiretroviral and immunosuppressive drug-drug interactions: an update. Kidney Int 2004; 66: 532-541.
19. Frassetto L, Baluom M, Jacobsen W et al. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation 2005; 80: 13-17.
20. Corsini A. The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. Cardiovasc Drugs Ther 2003; 17: 265-285.